Header Ads

Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Inc. (KPTI), is a clinical-stage pharmaceutical company that on Wednesday announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to selinexor, the Company’s first-in-class, oral SINE compound for the treatment of patients with diffuse large B-cell lymphoma. 

The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to address unmet medical needs. “The receipt of Fast Track designation from the FDA for selinexor underscores the great unmet medical need for this aggressive form of lymphoma,” said Sharon Shacham, Karyopharm CEO. 

On Friday, Wedbush analyst David Nierengarten upgraded shares to outperform from neutral (PT $19) saying current levels offer an “attractive entry point” ahead of initial Phase 2b “Sadal” data next month. He also said “I believe selinexor will be approved in multiple myeloma on its Pdufa date of April 6 and looking to additional Phase 2b “Storm” data at the ASH conference . 

I will be watching to see if KPTI could break through Fridays high of 12.49 and continue trading higher next week.

No comments

Powered by Blogger.